LLY's Call-Heavy Options Setup: A Bullish Catalyst at $1040–$1100 With RSI Overbought Warnings

Generated by AI AgentOptions FocusReviewed byAInvest News Editorial Team
Thursday, Nov 13, 2025 1:16 pm ET2min read
Aime RobotAime Summary

-

shares rose 1.15% to $1029.50 with RSI at 89.56, signaling overbought conditions.

- Call options dominate at $1040–$1100 strikes (OI: 9,985–10,659), reflecting aggressive bullish sentiment.

- Technical indicators show strong upward momentum, but risks of a pullback near $1040–$1070 persist due to overbought exhaustion.

- Price exceeds 20-day moving average by 19.6%, with MACD (48.56) and bullish K-line patterns reinforcing upside bias.

  • LLY trades at $1029.50, up 1.15% with RSI near overbought territory (89.56)
  • Call open interest dominates (277,891 vs. 211,239 puts), especially at $1040–$1100 strikes
  • MACD (48.56) and bullish K-line pattern suggest momentum is still charging higher
  • Bollinger Bands show current price is 19.6% above the 20-day moving average

Here’s the deal: LLY’s options market is screaming bullish, but technicals hint at a potential pause. The stock has a clear upside bias, but traders need to watch for overbought exhaustion near $1040–$1070.

Call Dominance at $1040–$1100 Signals Aggressive Bullish Sentiment

LLY’s options chain is a one-way street right now. For Friday expiration, the $1040 call (OI: 9,985) and $1100 call (OI: 10,659) are the most watched. That’s not just retail noise—those strikes represent a 1.3%–8.1% move from current price. Think about it: investors are betting big on a near-term pop, likely tied to earnings or drug approval optimism.

But here’s the catch: RSI is at 89.56, which is textbook overbought. Historically, stocks with RSI above 85 often see pullbacks. The question isn’t whether

can go higher—it’s whether the rally has already priced in the good news. The $1030–$1040 zone could act as a speed bump, especially if volume cools.

No Major News, But Options Tell a Story of Forced Optimism

The lack of headlines is interesting. No drug trial updates, no regulatory drama—just pure options-driven momentum. That means the market is pricing in expectations, not facts. Sometimes that’s a recipe for success (think pre-earnings hype). Other times? It’s a bubble waiting to pop.

Here’s what I mean: If Eli Lilly’s fundamentals don’t justify the $1100 strike (which is 7% above current price), the options buyers could get squeezed. But if the company surprises to the upside—even slightly—the $1040–$1070 calls could become gold. It’s a high-risk, high-reward setup.

Actionable Trade Ideas: Calls for the Bold, Stock for the Patient

For options traders: The $1040 call (Friday expiration) and $1080 call (next Friday) are your best bets. Why? The Friday $1040 call is already in play, with heavy open interest. If LLY breaks $1040, the $1080 next-week call could ride the momentum. Both strikes offer leverage if the stock gaps higher.

For stock players: Consider entry near $1010–$1020 if support holds. Your target? $1070–$1080 if the $1040 level is cleared. But set a stop-loss below $1000—that’s where the Bollinger Bands and 30-day MA converge. If the stock can’t hold there, the bullish case weakens fast.

Volatility on the Horizon: Positioning for a Breakout or Reversal

Let’s wrap this up with a reality check. LLY is in a tightrope walk: bullish momentum vs. overbought technicals. The options market is pricing in a 7%+ move, but the RSI says “don’t get too comfortable.”

Here’s your plan:

  • If LLY breaks $1040 cleanly, ride the $1080 call or stock position higher.
  • If it stalls below $1030, consider shorting the $1030–$1040 range with tight stops.
  • Keep an eye on next Friday’s $1140 call (OI: 1,541)—that’s where the “all-in” bulls are hiding.

The bottom line? This isn’t a “buy and hold” story. It’s a timing game. The options data gives you a roadmap, but the technicals are your seatbelt. Play it smart, and you might ride this rally all the way to $1100.

Comments



Add a public comment...
No comments

No comments yet